| Study name |
Clinical trial to assess the efficacy of μSmin® Plus (dietary supplement) |
| Methods |
Multicentre, randomised, double‐blind, parallel, placebo‐controlled trial |
| Participants |
68 participants adults with CVI between C2‐C4 on the CEAP classification system |
| Interventions |
1 tablet of μSMIN® Plus (corresponding to 450 mg of micronized diosmine) or placebo per day during 8 weeks |
| Outcomes |
QoL (CIVIQ‐20 questionnaire), VAS pain scale, CVI symptomatology, and change in the circumference of the affected leg at calf level, investigators and patient global assessment, percentage of subjects who would want to continue with the treatment, treatment compliance and safety |
| Starting date |
24 September 2019 |
| Contact information |
Contact: Dionisio Franco Barattini, MD
Contact: Dumitru‐Emanuel Dogaru, PM |
| Notes |
|
